Amplia Therapeutics |
High $0.08 |
Low $0.07 |
Trades 8 |
Turnover $9,058 |
Volume 120,981 |
| 30 June 2023 at 2:59pm | ||||
|
Market Cap (16-Nov) $46,198,080 (1,444th) |
Close (30-Jun) $0.076 |
Volume (30-Jun) 120,981 |
Shortsold (9-Nov) 30,144 (0.01%) (594th) |
|
52w High $0.275 |
52w Low $0.076 |
P/E - |
EPS -0.02 |
Registered Office and Principal Place of Business
ATX released this announcement to the ASX on 24 June 2022, 13:02. The announcement is not marked as price sensitive, and is 1 page(s) in length and 127.54kb in size.
You can view all announcements from ATX and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATX was 0.040% short sold according to ASIC data. It was ranked the 554th most shorted stock on the ASX. It remains ranked 594th as of the latest reported data (09 November 2026).
| Other Recent Announcements from ATX | |
|---|---|
| AMP945 International Nonproprietary Name Narmafotinib | 21 June 2023, 8:34 |
| Amplia AGM to be held Thursday 24 August 2023 | 19 June 2023, 17:34 |
| Key to Corporate Governance Disclosures | 31 May 2023, 8:14 |
| Registered Office and Principal Place of Business | 24 June 2022, 13:02 |
| Notification of Expiry of Unlisted Options | 9 June 2022, 16:49 |
| Application for quotation of securities - ATX | 9 June 2022, 16:29 |
| AMP945 Shows Efficacy in Model of Lung Fibrosis | 2 June 2022, 8:17 |
If you were already registered, log in here.